Pharmaceutical Industry discussion, review, analysis, news and information.

The European Union has granted conditional marketing authorization to Tibotec Pharmaceutical Ltd.’s new protease inhibitor (PI) darunavir (boosted with ritonivir; trade name Prezista™) as a new treatment in combination with Roche’s fusion inhibitor – FUZEON - for patients that are resistant to many HIV medications.

The combination of FUZEON and boosted darunavir has been shown to give treatment-experienced patients a better chance of achieving an undetectable viral load than boosted darunavir without FUZEON.

Darunavir is also known by the investigational compound number TMC114.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a division of Janssen-Cilag.

Source: Tibotec Pharmaceuticals